- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
GE Acquires Breast Ultrasound Developer U-Systems
GE Healthcare axquires U-Systems Inc., developer of the Automated Breast Ultrasound, a system used as a supplement to mammography for asymptomatic women with dense breasts and no prior interventions.
GE Healthcare announced last week the acquisition of U-Systems Inc., developer of a breakthrough ultrasound system approved for breast cancer screening.
U-Systems’ somo•v® Automated Breast Ultrasound (ABUS) was approved by the FDA in September as an adjunct to mammography for asymptomatic women with dense breasts and no prior breast interventions. The companies did not disclose the financial terms of the acquisition.
“The combination of U-Systems, Inc. and GE Healthcare uniquely positions GE to offer U.S. healthcare providers and their patients the most comprehensive portfolio of breast care innovations on the market - from screening to diagnosis to monitoring,” Tom Gentile, president and CEO of GE Healthcare Systems, said in a statement.
Studies have shown that women with dense breast tissue are at a greater risk of breast cancer compared with those with little or no dense tissue.
"The worldwide resources of GE Healthcare will allow us to expand and accelerate our efforts to commercialize the recently FDA-Approved somo•v® ABUS,” Ron Ho, U-Systems president and CEO, said in a statement. “With our combined resources and capabilities, we have the opportunity to make a significant impact on breast cancer detection and patient outcomes around the world.”
Multicenter Study Shows Merits of AI-Powered Ultrasound Assessment for Detecting Ovarian Cancer
January 3rd 2025Adjunctive AI offered greater than seven percent increases in sensitivity, specificity, and accuracy for ultrasound detection of ovarian cancer in comparison to unassisted clinicians who lacked ultrasound expertise, according to findings from new international multicenter research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
